Korro Bio, Inc.
KRRO · XNASCIK 1703647fmd_0GWQAXARVM0F556W192G12KT8FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 29 | 37 | 14 | 0 | 0 | 2 | 6 |
| Net interest income | (0) | (0) | 2 | – | – | (0) | 0 | – | – |
| Realized investment gains (losses) | – | – | 0 | 0 | (0) | 0 | – | – | – |
| Research and development | 12 | 12 | 19 | 37 | 61 | 42 | 57 | 64 | 66 |
| Total operating expenses | 16 | 19 | 50 | 65 | 98 | 59 | 85 | 94 | 128 |
| Operating income | (16) | (19) | (21) | (28) | (84) | (59) | (85) | (92) | (122) |
| Interest expense | – | – | – | 0 | 1 | 1 | – | – | – |
| Interest and investment income | – | – | 2 | 1 | 0 | 1 | – | – | – |
| Other non-operating income (expense) | – | – | – | – | (0) | 1 | 3 | 8 | 5 |
| Income before taxes | – | – | (19) | (26) | (85) | (58) | (81) | (83) | (117) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | – | (19) | (27) | (85) | (58) | (81) | (84) | (117) |
| Net income | (20) | (19) | (19) | (27) | (85) | (58) | (81) | (84) | (117) |
| Net income to common shareholders | (20) | (19) | (20) | (27) | (85) | – | – | – | – |